This is a preview of subscription content, log in via an institution to check access.
Notes
2017 euros
Reference
Ghabri S, et al. Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France. Value in Health : 12 Feb 2020. Available from: URL: https://doi.org/10.1016/j.jval.2019.12.003
Rights and permissions
About this article
Cite this article
Costs lowest when bDMARD sequences start with etanercept biosimilar. PharmacoEcon Outcomes News 847, 8 (2020). https://doi.org/10.1007/s40274-020-6584-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6584-0